SPOTLIGHT: Xanodyne files IPO

After garnering a total of $232 million in venture funds to buy aaiPharma's pharmaceutical division out of bankruptcy, Xanodyne Pharmaceuticals--which has three products in development in addition to a number of marketed pharmaceuticals--is now planning to go public, filing an $86.2 million IPO. Apax Partners, MPM Capital, AIG, Essex Woodlands Health Ventures, HealthCare Ventures, Aisling Capital and Blue Chip Venture all have a stake in the company. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.